- Home
- REFI vs ALEC Comparison
REFI vs ALEC Comparison
Compare REFI & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | ALEC |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | N/A | 103 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.6M | 245.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | REFI | ALEC |
|---|---|---|
| Price | $11.36 | $2.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 138.3K | ★ 524.3K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,857,628.00 | $21,045,000.00 |
| Revenue This Year | $17.47 | $2.03 |
| Revenue Next Year | $0.06 | $29.87 |
| P/E Ratio | $49.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.74 | $1.09 |
| 52 Week High | $14.97 | $3.40 |
Technical Indicators
Market Signals| Indicator | REFI | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 47.32 |
| Support Level | $10.74 | $1.91 |
| Resistance Level | $12.45 | $2.62 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 18.75 | 30.22 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.